PureTech Health PLC (PRTC) Noticias

PureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial Officer

Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations PureTech Health plc...

PureTech to Present at Two Upcoming Investor Conferences

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the...

PureTech Founded Entity Seaport Therapeutics Closes $225 Million Oversubscribed Series B Financing Round

Financing led by General Atlantic with participation from other top tier investors Proceeds will support key clinical milestones in Seaport’s...

PureTech Presents Research Highlighting Burden of Idiopathic Pulmonary Fibrosis (IPF) and Use of a Bayesian Statistical Analysis for LYT-100 (Deupirfenidone) at CHEST 2024 Annual Meeting

IPF patient survey provides new insights into disease burden and patient experience one decade after the approval of the first antifibrotics for...

PureTech to Present at CHEST 2024 Annual Meeting

Three presentations inform clinical, commercial and patient engagement strategies for LYT-100 for the treatment of idiopathic pulmonary fibrosis...

PureTech-Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults

Milestone triggers payments to PureTech totaling $29 million under agreements with Royalty Pharma and PureTech’s Founded Entity, Karuna...

PureTech Founded Entity Vor Bio Announces New Clinical Data Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies

Trem-cel + Mylotarg demonstrated engraftment, shielding, broadened therapeutic window, and patient benefit VCAR33ALLO demonstrates encouraging...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

PureTech Health plc – Half-Year Report

Strong progress across PureTech’s portfolio, with significant near-term catalysts Robust shareholder returns enabled by Founded Entity1...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

PureTech Appoints Michele Holcomb, PhD, to Board of Directors

Strategic healthcare leader brings more than 30 years of global experience to PureTech’s Board following...

PureTech Health: Notice of Half-Yearly Results

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company") plans to announce its half-yearly results for the six months ended...

PureTech Founded Entity Seaport Therapeutics Appoints David Wheadon, M.D., to its Board of Directors

Prominent pharmaceutical leader from AstraZeneca, Abbott, GlaxoSmithKline and Eli Lilly, brings extensive regulatory affairs and clinical...

PureTech Founded Entity Vedanta Biosciences Expands Leadership Team and Appoints Head of Commercial

Appointments support ongoing Phase 2 COLLECTiVE202 trial of VE202, pivotal Phase 3 RESTORATiVE303 trial of VE303 and planning for commercial...